7月3日 - ** 药物开发商Summit Therapeutics SMMT.O股价上涨3%，至23.30美元
** 彭博新闻社（(link)）援引知情人士的话报导说，阿斯利康AZN.L正在与Summit洽谈合作事宜，将以高达150亿美元的价格获得一种肺癌药物ivonescimab的许可。
** 报导称，Summit 还在与其他大型制药公司商谈潜在合作事宜
** Summit 没有立即回应路透的置评请求，而阿斯利康发言人拒绝置评
** 包括本交易日在内，该股今年累计上涨 25.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.